From: Economic evaluation of pneumococcal conjugate vaccination in The Gambia
Outcomes | No vaccination | Vaccination (PCV7) | Vaccination (PCV10) | Vaccination (PCV13) |
---|---|---|---|---|
K = 0 (base-case) | Â | Â | Â | Â |
Cost (2005 US$) | 233,100 | 906,240 | 902,040 | 899,280 |
Incremental cost (2005 US$) | - | 673,140 | 668,940 | 666,180 |
Effectiveness (DALYs) | 182,630 | 181,890 | 181,630 | 181,450 |
Incremental effectiveness (DALYs averted) | - | 740 | 1,000 | 1,180 |
ICER (2005 US$/DALY averted) | - | 910 | 670 | 570 |
ICER expressed as % per capita GDPa | Â | 250% | 190% | 160% |
K = 1 | Â | Â | Â | Â |
Cost (2005 US$) | 233,100 | 906,240 | 902,040 | 899,280 |
Incremental cost (2005 US$) | - | 673,140 | 668,940 | 666,180 |
Effectiveness (DALYs) | 208,670 | 207,820 | 207,530 | 207,330 |
Incremental effectiveness (DALYs averted) | - | 850 | 1,140 | 1,340 |
ICER (2005 US$/DALY averted) | - | 800 | 590 | 500 |
ICER expressed as % per capita GDPa | Â | 220% | 160% | 140% |